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INTRODUCTION
Sex cord-stromal tumor of the ovary is an uncommon neo-
plasm that accounts for approximately 7% of all malignant
ovarian neoplasms (1, 2). Granulosa cell tumors (GCTs) are
derived from granulosa cells, a hormonally active component
of the ovarian stroma responsible for estradiol production.
Their rarity has limited our understanding of the natural his-
tory and management of this cancer. The usual natural his-
tory of GCTs is indolent, with a very favorable long-term
prognosis; however, relapses tend to occur, typically many
years after the original diagnosis.
There is no standard approach to the management of relaps-
ed GCT, and a combination of several modalities, such as sur-
gery followed by radiation or chemotherapy, have been asso-
ciated with prolonged disease-free survival (3, 4). However,
owing to the indolent and long history of GCTs, additional
therapeutic approaches, such as hormonal therapy, are requir-
ed. Although a considerable rationale exists for the use of hor-
monal therapy in GCTs, clinical experience with this approach
is extremely limited. 
Here, we present a case in which a gonadotropin-releasing
hormone (GnRH) agonist was successfully used to treat recur-
rent disease in a woman with a granulosa cell tumor, which
had failed to respond to systemic chemotherapy and surgery. 
CASE REPORT
A 65-yr-old multiparous woman presented 17 yr status
post-hysterectomy with bilateral ovarian salpingo-oophorec-
tomy, attributable to ovarian cancer. She had not received adju-
vant therapy because of intolerance and she had not under-
gone regular follow-up monitoring. After 7 yr, she visited
another hospital for abdominal pain, and she found that she
had relapsed, developing multiple liver masses with granu-
losa cell tumors, and underwent three cycles of transarterial
chemotherapy with cisplatin (100 mg/m
2) without systemic
chemotherapy. The response to transarterial chemotherapy
was not fully determined. We could not get additional infor-
mation regarding her medical information, because of limi-
tations at the other institute and the long time gap. Ten years
after the transarterial chemotherapy, without any regular fol-
low-up monitoring, she was admitted via our emergency room
because of abdominal pain and hematuria. She presented with
multiple cystic liver masses, multiple large seeded masses in
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GnRH Agonist Therapy in a Patient with Recurrent Ovarian Granulosa
Cell Tumors
A 65-yr-old woman presented 17 yr status post-hysterectomy with bilateral ovarian
salpingo-oophorectomy, attributable to ovarian cancer. She was admitted to our
hospital, with multiple cystic liver masses and multiple large seeded masses in her
abdomen and pelvic cavity. Histological examination of the pelvic masses demon-
strated granulosa cell tumors. After two courses of systemic combination chemother-
apy, with paclitaxel and carboplatin, the masses in the abdomen and pelvic cavity
increased, and debulking surgery also failed because of peritoneal dissemination
with severe adhesion. Finally, she underwent palliative radiotherapy for only the
pelvic masses obstructing the urinary and GI tracts, and monthly hormonal thera-
py with a gonadotrophin-releasing hormone agonist; leuprorelin 3.75 mg IM. Sub-
sequently, multiple masses beyond the range of the radiation as well as those with-
in the radiotherapy field partially decreased. This partial response had been main-
tained for more than 8 months as of the last follow-up visit. Owing to its long and
indolent course and the low metabolic rate of the tumors, advanced or recurrent
granulosa cell tumor (GCT) requires treatment options beyond chemotherapy, sur-
gery, and radiotherapy. Hormonal agents may provide another treatment option
for advanced or recurrent GCT in those who are not candidates for surgery, che-
motherapy, or radiotherapy.
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Accepted : 12 March 2008the abdomen and pelvic cavity, and hydronephrosis of her left
kidney (Fig. 1A). The masses were recognized as hypometa-
bolic by positron emission tomography-computed tomography
(PET-CT) (Fig. 1B). Histological examination of the pelvic
masses demonstrated granulosa cell tumors that were nega-
tive for estrogen receptor (ER), positive for progesterone recep-
tor (PR), and positive for inhibin (Fig. 2).
The patient received two cycles of systemic combination
chemotherapy with paclitaxel (175 mg/m
2) and carboplatin
(AUC 5) every 3 weeks. However, the masses in the abdomen
and pelvic cavity increased, resulting in difficulty in voiding
and defecation (Fig. 1C). Finally, we tried debulking surgery,
536 H.J. Kim, S.-C. Lee, S.B. Bae, et al.
Fig. 1. Images before and after treatments. (A) A CT scan performed before systemic chemotherapy shows multiple metastatic masses in
the abdomen and pelvis. (B) A PET scan performed before systemic chemotherapy shows multiple hypometabolic masses in the abdomen
and pelvis. (C) A CT scan performed before radiotherapy and hormonal therapy shows multiple metastatic masses with increased size in
the abdomen and pelvis. (D) A CT scan performed after radiotherapy and hormonal therapy shows a partial response to this therapy. The
insert shows a radiotherapy planning radiography.
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Fig. 2. Photomicrographs of recurrent granulosa cell tumor. Note the classic grooved nuclei, known as “coffee bean” nuclei, in the malignant
granulosa cells (A: H&E,×40; B: H&E, ×400) and the positive immunohistochemical staining for inhibin (C: ×400), progesterone receptor
(E: ×400), and negative staining with estrogen receptor (D: ×400).
A
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Bdespite the multiple disseminated disease status, for pallia-
tion. The debulking surgery failed because of peritoneal dis-
semination, with severe adhesion to the bowel and retroperi-
toneum; thus, she underwent a colostomy. 
Subsequently, her performance status declined, but she did
not want any further chemotherapy. After surgery, she under-
went palliative radiotherapy (6,000 cGY/30 Fr) for the pelvic
masses obstructing her urinary tract and bowel, and monthly
hormonal therapy with a GnRH agonist (leuprorelin 3.75
mg IM). She tolerated this treatment without difficulty. One
month after completing radiotherapy and after three GnRH
agonist injections, a CT scan revealed that the multiple seed-
ed masses, including those both within and beyond the radio-
therapy field, had partially decreased (Fig. 1D). Her partial
response was calculated as 36.5% decreased, using the Res-
ponse Evaluation Criteria in Solid Tumors (RECIST) criteria,
for the target lesions in the abdominal cavity, excluding the
pelvic mass. With the change in the tumors, her blood estra-
diol level decreased (Fig. 3). The partial response had been
maintained for more than 8 months as of her last follow-up
visit. Currently, the patient is doing well, with no discom-
fort or pain, and continues to receive hormonal therapy. 
DISCUSSION
Granulosa cell tumors are uncommon, and thus experience
in managing this tumor is limited. There is no standard appr-
oach to the management of relapsed GCTs, although a com-
bination of approaches, including surgery followed by radi-
ation or chemotherapy, has been associated with prolonged
disease-free survival in some series (3, 4). Regarding chemo-
therapy as a treatment modality, platinum-based regimens
have been the treatment of choice for the past decade and are
the preferred option for treating widespread disease or disease
that is suboptimally cytoreduced at the time of relapse. 
There are limited data on the use of radiation therapy in the
treatment of GCTs. Wolf et al. (4) showed a 43% response
rate in patients with advanced stage or recurrent GCT who
were treated with whole abdomen irradiation or pelvic irra-
diation. Some case reports describe the use of radiation treat-
ment for isolated liver or bone recurrences (5, 6). However,
there is no clear role for radiotherapy because of the lack of
uniformity in staging and in treatment regimens. 
In the present case, the outcome of chemotherapy was dis-
appointing. The low metabolic rates of the masses recognized
by PET-CT may have been the reason for the limited effect
of chemotherapy. In addition, the irradiation of the whole
abdomen or the pelvic cavity in this case was very challeng-
ing because of the large tumor size the disseminated status
of the cancer. Thus, other treatment options were needed in
this case. 
GCT is a hormonally active tumor, and thus it seemed rea-
sonable to assess whether hormonal agents might be active
against these tumors. There have been several reports about
the hormonal therapy of GCTs with GnRH agonists, aromat-
ase inhibitors, or megesterol (7-11). Several mechanisms have
been suggested for how hormone manipulation may inhibit
tumor growth in GCT (11-14). These can be categorized as
indirect action on tumors via suppression of gonadotropins
or endogenous steroids and direct effects on the tumor via a
local mechanism mediated by specific receptors in the GCT.
A proportion of GCTs expresses receptors for follicle stimulat-
ing hormone (FSH), which has been shown to support the
growth of GCTs in nude mice (15). Thus, hormonal thera-
pies that can decrease gonadotropins may block the stimu-
latory effects on granulosa cells. GnRH agonists have previ-
ously been used in other hormonally regulated cancers, such
as breast and prostate cancer (16, 17). Estrogen stimulates
proliferation of granulosa cells by increasing the cells’ respon-
siveness to FSH, thus, anti-estrogens may have anti-prolifer-
ative activity in GCT. In addition, progestins were suggest-
ed as chemopreventive agents by inducing apoptosis pathway
involving transforming growth factor (TGF-α ) in ovarian epi-
thelium, a plausible local mechanism for inhibiting tumor
growth (18). However, experience in treating GCT with hor-
monal agents is limited. Although several studies have report-
ed the successful use of GnRH agonists (7, 8), negative results
have also been reported (9). Furthermore, hormonal therapy
has been attempted in cases of progressive GCTs that have
failed to respond to chemotherapy and/or radiation. Based on
the clinical course and performance status in our case, we con-
sidered hormonal treatment to be appropriate. 
The hormonal activity of GCTs permits the use of a variety
of tumor markers for postoperative surveillance. Estradiol was
one of the first substances identified as being secreted by GCTs
and is responsible for some of the clinical manifestations. How-
ever, there was no consistent correlation between the estradiol
level and GCT progression in a previous report (19). In our
case, the estradiol level appeared to correlate with the clini-
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Fig.3. The estradiol levels according to therapies. 
Pre-CT, pre-chemotherapy; Post-CT, post-chemotherapy; Post Op,
post-operation; Pre-RT/HT, pre-radiotherapy/hormone therapy;
Post-RT/HT, post-radiotherapy/hormone therapy; Post-HT, post-
hormone therapy.
Pre-CT
Post-CT
Post-Op,
Pre-RT/HT
Post-RT/HT#1
Post-HT#2
Post-HT#3
Post-HT#4cal course. Larger studies are needed to further examine the
usefulness of estradiol as a marker for monitoring the status
of GCT patients.
The natural course of GCT usually involves a very long his-
tory, and relapse can occur many years after the initial diag-
nosis. Owing to its long and indolent course and the low me-
tabolic rate of the tumors, advanced or recurrent GCT requires
treatment options beyond chemotherapy, surgery, and radio-
therapy. Hormonal agents may provide another treatment
option for advanced or recurrent GCT in those who are not
candidates for surgery, chemotherapy, or radiotherapy. 
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